Hmm.. I didn't care for the PR but I'm adding a few shares on dips.
I'd really prefer that Leo shout from the rooftops after we have statistical confirmation of initial Phase 2B impressions. Clearly, he's drawing attention to Cellceutix's defensin mimetic portfolio while antibiotic resistance is in the headlines. I get it.
In my view, he'll have plenty of opportunities to draw attention to the company when he is armed with data and it will carry a lot more weight. The issue of antibiotic resistance is not going to go away. To me it seems like unnecessary hype. Show me the money.
Market Data 
Markets 
AI
